The observed dose-response relationship between baseline BMI and age with cardiovascular efficacy aligns with recent trials showing that GLP-1 RAs may be especially effective in populations at elevated metabolic and cardiovascular risk such as those who have obesity and CVD. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.